Revvity, Inc. today announced it has entered into a definitive agreement to acquire ACD/Labs, a global provider of scientific software solutions that support analytical characterization and molecular design across pharmaceutical and material sciences end markets. This acquisition expands the breadth and depth of Revvity Signals’ solutions for bridging the gap between analytical data and actionable insights, further strengthening its ability to accelerate scientific innovation.

Revvity, Inc. 今天宣布已达成最终协议，将收购 ACD/Labs。ACD/Labs 是一家全球性的科学软件解决方案提供商，支持制药和材料科学终端市场中的分析表征和分子设计。此次收购拓展了 Revvity Signals 解决方案的广度和深度，弥合了分析数据与可操作见解之间的差距，进一步增强了其加速科学创新的能力。

The transaction is expected to close late in Q4 2025..

该交易预计将在2025年第四季度末完成。

ACD/Labs brings deep expertise in supporting analytical and process chemistry within pharmaceutical and chemical R&D workflows. Its industry-leading tools help scientists identify and characterize molecules, monitor purity and quality, and deliver robust production processes. Together, Revvity Signals and ACD/Labs will provide comprehensive support across the scientific workflow—from discovery and development to scale-up and manufacturing— giving scientists the ability to interpret, manage, and act on complex data with greater speed and confidence..

ACD/Labs在支持制药和化工研发工作流程中的分析和工艺化学方面具有深厚的专业知识。其行业领先的工具帮助科学家识别和表征分子、监控纯度和质量，并提供强大的生产流程。Revvity Signals与ACD/Labs将共同为科学工作流程提供全面支持——从发现、开发到扩大规模和生产，使科学家能够更快、更自信地解读、管理和处理复杂数据。

ACD/Labs’ industry-leading tools include:

ACD/Labs 行业领先的工具包括：

“By integrating ACD/Labs’ technologies into the Revvity Signals platform, we’re giving our customers across pharmaceuticals and material sciences a truly unified SaaS environment—one that connects molecular design, analytical science, and manufacturing quality control within a single, end-to-end solution,” said Kevin Willoe, president of Revvity Signals Software.

“通过将ACD/Labs的技术整合到Revvity Signals平台中，我们为制药和材料科学领域的客户提供了真正统一的SaaS环境——这一环境在一个端到端的解决方案中，将分子设计、分析科学和制造质量控制连接在一起，”Revvity Signals软件总裁Kevin Willoe表示。

“This acquisition adds meaningful value to our portfolio and reinforces the importance of analytical sciences as a driver of innovation across disciplines.”.

“此次收购为我们的投资组合增添了重要的价值，并加强了分析科学作为跨学科创新驱动力的重要性。”

“For more than three decades, our scientists, informaticians, and software developers have been recognized as leaders in analytical and chemical intelligence,” said Daria Thorp, president and CEO of ACD/Labs. “Joining the Revvity Signals team brings together two industry leaders with a shared commitment to innovation in scientific software.

“三十多年来，我们的科学家、信息学家和软件开发人员一直被认为是分析和化学智能领域的领导者，”ACD/Labs总裁兼首席执行官达莉亚·索普说。“加入Revvity Signals团队汇集了两位行业领导者，他们共同致力于科学软件的创新。”

Together, we will expand the reach of our technology and deliver unified, end-to-end solutions that empower customers with deeper insight and greater scientific continuity.”.

我们将共同扩大技术的影响力，提供统一的端到端解决方案，让客户获得更深入的洞察和更高的科学连续性。

Factors Affecting Future Performance

影响未来表现的因素

This press release contains “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to estimates and projections of future earnings per share, cash flow and revenue growth and other financial results, developments relating to our customers and end-markets, and plans concerning business development opportunities, acquisitions and divestitures.

本新闻稿包含1995年《私人证券诉讼改革法案》意义上的“前瞻性”声明，包括但不限于有关未来每股收益、现金流和收入增长及其他财务结果的估计和预测、与我们的客户和终端市场相关的发展，以及关于业务发展机会、收购和剥离的计划。

Words such as “believes”, “intends”, “anticipates”, “plans”, “expects”, “estimates”, “projects”, “forecasts”, “will” and similar expressions, and references to guidance, are intended to identify forward-looking statements. Such statements are based on management's current assumptions and expectations and no assurances can be given that our assumptions or expectations will prove to be correct.

诸如“相信”、“意图”、“预期”、“计划”、“预计”、“估计”、“预测”、“展望”、“将”等词语以及类似表述和对指导性信息的引用，旨在识别前瞻性陈述。此类陈述基于管理层当前的假设和预期，但无法保证我们的假设或预期一定会被证明是正确的。

A number of important risk factors could cause actual results to differ materially from the results described, implied or projected in any forward-looking statements. These factors include, without limitation: (1) markets into which we sell our products declining or not growing as anticipated; (2) fluctuations in the global economic and political environments, including as the result of recently implemented and recently threatened tariff increases; (3) our failure to introduce new products in a timely manner; (4) our ability to execute acquisitions and divestitures, license technologies, or to successfully integrate acquired businesses or licensed technologies into our existing businesses or to make them profitable; (5) our ability to compete effectively; (6) fluctuation in our quarterly operating results and our ability to adjust our operations to address unexpected changes; (7) significant disruption in third-party package delivery and import/.

可能导致实际结果与任何前瞻性声明中描述、暗示或预测的结果存在重大差异的重要风险因素包括但不限于：(1) 我们产品销售市场的下滑或未如预期增长；(2) 全球经济和政治环境的波动，包括由于最近实施和威胁的关税增加所导致的影响；(3) 我们未能及时推出新产品；(4) 我们执行收购和资产剥离、技术授权的能力，或成功将收购业务或许可技术整合到现有业务中并使其盈利的能力；(5) 我们有效竞争的能力；(6) 我们季度经营业绩的波动以及调整运营以应对意外变化的能力；(7) 第三方包裹运输和进口的重大中断。

About Revvity

关于Revvity

At Revvity, “impossible” is inspiration, and “can’t be done” is a call to action. Revvity provides health science solutions, technologies, expertise and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what’s possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more..

在Revvity，“不可能”是灵感，“无法做到”是行动的号召。Revvity提供健康科学解决方案、技术、专业知识和服务，涵盖从发现到开发、从诊断到治疗的完整工作流程。Revvity正在革新医疗领域的可能性，专注于转化多组学技术、生物标志物识别、成像、预测、筛选、检测与诊断、信息学等专业领域。

With 2024 revenue of more than $2.7 billion and approximately 11,000 employees, Revvity serves customers across pharmaceutical and biotech, diagnostic labs, academia and governments. It is part of the S&P 500 index and has customers in more than 160 countries.

2024年收入超过27亿美元，拥有约11,000名员工，Revvity为制药和生物技术公司、诊断实验室、学术界及政府部门提供服务。该公司是标准普尔500指数成分股之一，业务遍及160多个国家。

Stay updated by following our Newsroom, LinkedIn, X, YouTube, Facebook and Instagram.

通过关注我们的新闻室、LinkedIn、X、YouTube、Facebook 和 Instagram，随时了解最新动态。

About ACD/Labs

关于ACD/Labs

ACD/Labs is a leading provider of scientific software, aiding decision-making and digital transformation in chemical and pharmaceutical R&D.

ACD/Labs 是领先的科学软件提供商，助力化学和制药研发中的决策和数字化转型。

Our science-centric solutions offer harmonized, AI-ready analytical, structural, and molecular information, with FAIR-compliance. Our cloud-enabled technologies enable the proliferation of chemically intelligent knowledge and workflow automation.

我们的以科学为中心的解决方案提供符合FAIR标准的、可人工智能处理的分析、结构和分子信息。我们基于云的技术促进了化学智能知识的普及和工作流程的自动化。

For 30 years, we have partnered with global organizations to enhance productivity and accelerate scientific innovation. For more information, please visit www.acdlabs.com. Follow us on X (Twitter) and LinkedIn.

三十年来，我们一直与全球组织合作，以提高生产力并加速科学创新。欲了解更多信息，请访问 www.acdlabs.com。请在 X（Twitter）和 LinkedIn 上关注我们。

Media Relations:

媒体关系：

Chet Murray

切特·默里

(781) 462-5126

(781) 462-5126

chet.murray@revvity.com

chet.murray@revvity.com

Investor Relations:

投资者关系：

Steve Willoughby

史蒂夫·威洛比

steve.willoughby@revvity.com

史蒂夫·威洛比@revvity.com

Source: revvity.com

来源：revvity.com